Experiences with
Imbruvica843 public posts
Want to take advantage of all our features? Just log in!
or
Ibrutinib/Imbruvica brings hope to stem cell transplant patients with chronic graft-versus-host-disease
[i]'FDA granted a fourth Breakthrough Therapy Designation (BTD) for ibrutinib (IMBRUVICA®) as a potential treatment of chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.
What about Duvelisib and CLL?
[http://cllsociety.org/2016/05/fda-expands-imbruvica-label-include-os-data-plus-new-indication-sll/]
THANK YOU AGAIN TO OUR READER POLL PARTICIPANTS! Data analysis is in progress and we are really excited with the preliminary results.
Dr Susan O'Brien Sheds Light on Role of Next-Generation Agents in CLL
[/i]
OncLive interview with Dr O'Brien:
http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll
Drugs mentioned:
ibrutinib (Imbruvica)
idelalisib (Zydelig)
duvelisib in trial versus ofatumumab (Arzerra)
TGR-1202 (PI3K inhibitor)
acalabrutinib, (ACP-196) a
Atrial Fibrillation, Warfarin Use May Increase Dementia Risk
Press-Releases/2016/05/New-Study-Shows-Atrial-Fibrillation-Patients-Treated-With-Warfarin-Long-Term-Are-At-Increased-Risk-For-Dementia
While we are at an increased age related risk of developing Atrial Fibrillation, there is also approximately a 5% risk of developing this condition while taking Ibrutinib/Imbruvica
Waldenstrom’s Macroglobulinemia Patient & Caregiver Surveys
Survey for WM Patients with Ibrutinib (Imbruvica) Experience
- https://www.surveymonkey.com/r/V3GVWCT
Survey for WM Patients who have NOT been treated with Ibrutinib (Imbruvica)
- https://www.surveymonkey.com/r/V9DKRQQ
Survey for Caregivers
- https://www.surveymonkey.com/r/V93DT3J
Please share
CLL Patient Survey
If you have CLL and have been treated with either ibrutinib (Imbruvica) or venetoclax (ABT-199) we need your help.
Imbruvica Approved Frontline in the USA!
http://www.prnewswire.com/news-releases/imbruvica-ibrutinib-approved-by-us-fda-for-the-first-line-treatment-of-chronic-lymphocytic-leukemia-300231107.html